Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, considers the role of CDK4/6 inhibitors in the management of metastatic triple-negative breast cancer (TNBC)

Tags: BreastESMO 2019

Published: 30 September 2019

Recent Videos

video

Robert Coleman, MD, describes experience with virtual ASCO20

Dr. Coleman, Chief Scientific Officer, US Oncology Network, describes experience with virtual ASCO20

video

Joyce Liu, MD, describes experience with virtual ASCO20

Dr. Liu, Assistant Professor of Medicine, Dana-Farber Cancer Institute, describes experience with virtual ASCO20

video

Sara Hurvitz, MD, describes the recently reported results using PARP inhabitation and cisplatin

Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, describes the recently reported results using PARP inhibition with and without ...

video

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, discusses the recently announced results of both the Monarch E ...

video

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, shares the design and outcomes of the HER2CLIMB study investigating tucatinib ...

video

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients

Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, describes the evolving role of PARP inhibitors in breast cancer ...

video

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, introduces new information regarding CDK4/6 inhibitors for hormone receptor positive ...

video

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment

Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, reports on presentations presented at ASCO20 pertaining to immunotherapy in ...

video

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, provides his perspective on tucatinib and the HER2CLIMB study presented ...

video

Toni Choueiri, MD, describes potential importance of combining ipi/nivo for 1st line renal cell carcinoma patients

Dr. Choueiri, Professor of Medicine, Dana Farber Cancer Institute, describes his treatment strategy when a newly diagnosed renal cell carcinoma ...

Related Videos

video-image

Joyce Liu, MD, describes experience with virtual ASCO20

video-image

Robert Coleman, MD, describes experience with virtual ASCO20

video-image

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

video-image

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

video-image

Sara Hurvitz, MD, describes the recently reported results using PARP inhabitation and cisplatin

video-image

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

video-image

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment

video-image

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

video-image

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients

video-image

Dana Chase, MD, FACOG, summarizes the outcomes of the NRG-GY004 phase III study in ovarian cancer

video-image

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study

video-image

Dana Chase, MD, FACOG, provides thoughts on the clinical evidence of secondary cytoreductive surgery

video-image

Dana Chase, MD, FACOG, shares thoughts on the role of I-O in GTT management

video-image

Toni Choueiri, MD, describes treatment strategies for 2nd line renal cell carcinoma

video-image

Derek Raghavan, MD, discusses Mobile screening Chest CT project for use in underserved populations

video-image

Toni Choueiri, MD, describes potential importance of combining ipi/nivo for 1st line renal cell carcinoma patients

video-image

Derek Raghavan, MD, on the role of nephrectomy in the age of targeted therapies and immunotherapy

video-image

Derek Raghavan, MD, provides a general overview of prostate cancer therapies

video-image

Derek Raghavan, MD, explains toxicities and factors determining GNRH-based therapies selection

video-image

Derek Raghavan, MD, discusses the efficacy and utility of the new GNRH antagonist, Reugolix